Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

While there is not currently a shortage of Ozempic, previous difficulties in supplying this medication have led to some pharmacies offering compounded semaglutide. The Food and Drug Administration ...

This contrasts with the currently approved oral GLP-1 RA semaglutide (Rybelsus, Novo Nordisk), a peptide which ideally should be taken fasting and with no food or water for at least 30 minutes ...

The committee noted that semaglutide tablets 3 mg, 7 mg, and 14 mg are approved for marketing in India. The firm has claimed that Semaglutide tablets 1.5 mg, 4 mg, and 9 mg of the new formulation are ...

Conversely, Lilly's stock price jumped about 14.5% to $840. “While Novo had the headstart with approval of semaglutide, we believe that this first mover advantage has waned, with Lilly's ...

Although different active ingredients - Mounjaro is tirzepatide and Ozempic and Wegovy is semaglutide - they all work by mimicking hormones that tell the brain the stomach is full, releasing ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. The phase 3 study linked the oral GLP-1 drug orforglipron to similar reductions in blood glucose and body ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes were for GLP-1 receptor agonists, such as semaglutide or tirzepatide. New ...